U2TH34 Stock Overview
A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for U2TH34 from our risk checks.
United Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$108.01 |
| 52 Week High | US$121.08 |
| 52 Week Low | US$54.20 |
| Beta | 0.56 |
| 11 Month Change | 8.19% |
| 3 Month Change | 12.51% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 87.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| U2TH34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -6.3% | 1.2% | 0.9% |
| 1Y | n/a | 9.3% | -0.4% |
Return vs Industry: Insufficient data to determine how U2TH34 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how U2TH34 performed against the BR Market.
Price Volatility
| U2TH34 volatility | |
|---|---|
| U2TH34 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 8.1% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: U2TH34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine U2TH34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,168 | Martine Rothblatt | www.unither.com |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
United Therapeutics Corporation Fundamentals Summary
| U2TH34 fundamental statistics | |
|---|---|
| Market cap | R$96.65b |
| Earnings (TTM) | R$6.45b |
| Revenue (TTM) | R$16.00b |
15.0x
P/E Ratio6.0x
P/S RatioIs U2TH34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| U2TH34 income statement (TTM) | |
|---|---|
| Revenue | US$2.76b |
| Cost of Revenue | US$304.80m |
| Gross Profit | US$2.45b |
| Other Expenses | US$1.34b |
| Earnings | US$1.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 24.88 |
| Gross Margin | 88.94% |
| Net Profit Margin | 40.31% |
| Debt/Equity Ratio | 6.6% |
How did U2TH34 perform over the long term?
See historical performance and comparison